Cell line for enhancing functions of HBoV1 auxiliary system, improved HBoV1 auxiliary system and application of improved HBoV1 auxiliary system in efficient auxiliary AAV replication

By overexpressing the XPO5 gene and modifying the BocaSR sequence in cell lines, an improved HBoV1 helper system was constructed, which solved the problem of low efficiency of the HBoV1 helper system, improved the efficiency of AAV replication and packaging, and reduced the cost of gene therapy drugs.

CN118931844APending Publication Date: 2024-11-12HENAN UNIVERSITY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410999549.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing HBoV1 assist system has low efficiency in assisting AAV replication, resulting in high costs for AAV vector gene therapy drugs and insufficient progeny virus production.

Method used

An improved HBoV1 helper system was constructed by overexpressing the XPO5 gene in cell lines and modifying the nucleotide sequence of BocaSR, including plasmids expressing NP1 and NS2 and a modified BocaSR plasmid, to improve AAV replication and packaging efficiency.

Benefits of technology

It significantly increased the yield of AAV progeny viruses, reduced the cost of gene therapy drugs, and improved the efficiency of AAV replication and packaging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931844A_ABST
    Figure CN118931844A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and relates to an AAV (Adeno-Associated Virus), in particular to a cell line for enhancing the function of an HBoV1 auxiliary system, an improved HBoV1 auxiliary system and application of the improved HBoV1 auxiliary system in efficient auxiliary AAV replication. The application finds that XPO5 can improve the copying and packaging efficiency of non-coding RNA (BocaSR) in a human bocavirus system to assist AAV. According to the present invention, four kinds of the modified BocaSR capable of improving AAV duplication and packaging efficiency are invented by simultaneously modifying the BocaSR, and the modified BocaSR can be delivered into cytoplasm by XPO5 so as to provide effects of PKR activity inhibition in cells. The AAV capsid protein expression is promoted, the AAV genome replication is enhanced, the virus yield of a gene therapy drug taking AAV as a carrier clinically can be further improved, the gene therapy cost is greatly reduced, and the development potential is extremely high.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to adeno-associated viruses, and in particular refers to a cell line for enhancing the function of an HBoV1 auxiliary system, an improved HBoV1 auxiliary system and its application in efficiently assisting AAV replication. Background Art

[0002] Adeno-associated virus (AAV) is a replication-deficient virus that requires the help of other helper viruses such as adenovirus or herpes simplex virus to complete replication. AAV has the advantages of high safety, extremely low immunogenicity, a wide range of infected hosts, strong diffusion ability, stable expression and high tissue specificity, making it the most commonly used vector for gene therapy. However, due to the low efficiency of AAV replication and packaging, the cost of gene therapy drugs using AAV as a vector on the market is relatively high. Therefore, it is very necessary to develop a new and efficient AAV-assisted system. The commonly used AAV auxiliary systems include the adenovirus (AdV) auxiliary system, whose main components for assisting AAV replication are E2A protein, E4orf6 protein and non-coding RNA (VAI); the herpes simplexvirus 1 (HSV-1) auxiliary system, whose components are HSV-1 helicase-primer complex (HP; UL5 / UL8 / UL52) and UL29 gene; and the human bocavirus 1 (HBoV1) auxiliary system discovered in 2017, whose components for assisting AAV replication are HBoV1's NP1 protein, NS2 protein and HBoV1's own non-coding RNA (Bocavirus-transcribed small RNA, BocaSR). The adenovirus auxiliary system and the bocavirus auxiliary system are similar in composition, both of which are two proteins and one non-coding RNA. The function of VAI in the AdV auxiliary system is known, which can inhibit PKR activity and promote the synthesis of AAV capsid protein and replication-related proteins. However, the existing HBoV1 auxiliary system has low efficiency in assisting AAV replication, low yield of progeny viruses, and high cost when meeting actual needs. Therefore, it is necessary to transform the HBoV1 auxiliary system and improve its auxiliary efficiency. Summary of the invention

[0003] In view of the problems of low AAV progeny virus yield and high production cost on the market, which lead to the expensive price of gene therapy drugs corresponding to AAV vectors, the present invention proposes a cell line with enhanced HBoV1 auxiliary system function, an improved HBoV1 auxiliary system and its application in efficiently assisting AAV replication; four methods for improving the improved HBoV1 auxiliary system and their application in efficiently assisting AAV replication are proposed, thereby achieving the effect of improving the replication and packaging efficiency of AAV and increasing the yield of AAV progeny viruses.

[0004] The technical solution of the present invention is achieved in this way: In one aspect, the present application provides a cell line for enhancing the function of the HBoV1 helper system, wherein the cell line contains an XPO5 gene overexpression vector.

[0005] The above cell line is a mammalian cell line or a cancer cell line, such as a HEK293 cell line or a HeLa cell line; the XPO5 gene overexpression vector is obtained by inserting the XPO5 gene into a PCDH-3xFLAG vector.

[0006] The present invention screened host cell factors that can regulate the efficiency of AAV replication assisted by the HBoV1 auxiliary system and found that knocking down the XPO5 gene can significantly regulate it. The function of XPO5 was further verified, and the level of AAV progeny virus production was improved by exogenous overexpression of XPO5, transfection of NP1 and NS2, BocaSR and AAV plasmids in the HBoV1 auxiliary system.

[0007] On the other hand, the present application provides an HBoV1 helper system, comprising a plasmid expressing NP1 and NS2 and a plasmid expressing BocaSR.

[0008] The nucleotide sequence of BocaSR in the HBoV1 auxiliary system is shown in SEQ ID No. 1, and its mutant BocaSR is respectively BocaSR G139T (G mutated to T at position 139), BocaSR A1C (A mutated to C at position 1), BocaSR 12-G / AT139 (A added at position 12, G mutated to T at position 139) and BocaSR 1A- / CA12 (A at position 1 is mutated to C, and A is added at position 12) Its nucleotide sequence is shown in SEQ ID No.2, SEQ ID No.3, SEQ ID No.4 or SEQ ID No.5.

[0009] On the third aspect, the present application also protects the use of the above-mentioned HBoV1 auxiliary system in efficiently assisting AAV replication.

[0010] In a fourth aspect, the present application provides a method for improving the replication level of AAV, characterized in that the steps are: (1) Constructing an overexpression vector of the XPO5 gene and transferring it into a transfected cell line to overexpress the XPO5 protein; (2) By transfecting the transfected cell line in step (1) with plasmids expressing NP1 and NS2, a plasmid expressing BocaSR, and a plasmid expressing AAV2, the AAV replication level can be increased.

[0011] In the above step (1), the transfected cell line is a mammalian cell line or a cancer cell line, such as a HEK293 cell line or a HeLa cell line.

[0012] In the above step (2), the plasmids for expressing NP1 and NS2 are obtained by inserting the NP1 and NS2 genes into pCDNA3.1-FLAG, PCDNA3.1-MyC or pEGFP-C2 plasmids, and the plasmid for expressing AAV2 is the pIAAV2 plasmid.

[0013] The plasmid expressing BocaSR is obtained by inserting the sequence of mutant BocaSR into the PGEM-3Z or pLKO.1 plasmid, wherein the sequence of mutant BocaSR is shown in SEQ ID No.2, SEQ ID No.3, SEQ ID No.4 or SEQ ID No.5.

[0014] The addition ratio of the above-mentioned plasmids expressing NP1 and NS2, the plasmid expressing BocaSR, and the plasmid expressing AAV2 was 2:1:1.

[0015] This application is to transform four modified BocaSR G139T 、BocaSR A1C 、BocaSR 12-G / AT139 and BocaSR 1A- / CA12 The NP1NS2 and AAV plasmids in the HBoV1 auxiliary system were transfected into HEK293 cells respectively. After 48 hours, western blot experiments showed that the expression of AAV capsid protein VP produced by the BocaSR-composed Boca virus auxiliary system assisted AAV replication increased. The BocaSR non-coding RNA in the Boca virus auxiliary system was modified to improve the efficiency of AAV replication and packaging assisted by the Boca virus auxiliary system, and to increase the yield of AAV progeny viruses.

[0016] The present invention has the following beneficial effects: This application found that XPO5 can improve the efficiency of non-coding RNA-BocaSR (small RNA transcribed by human bocavirus, Bocavirus-transcribed small RNA, referred to as BocaSR) in the human bocavirus system that assists adeno-associated virus (AAV) replication and assists AAV replication and packaging, and increases the level of AAV progeny virus production by 3.10 times. At the same time, BocaSR was modified, and 4 modified BocaSRs that can improve the efficiency of AAV replication and packaging were invented. These modified BocaSRs can be transported to the cytoplasm through XPO5 and inhibit the activity of PKR (protein kinase R, referred to as PKR) in the cell. Promoting the expression of AAV capsid protein and enhancing the replication of AAV genome can further increase the virus yield of gene therapy drugs using AAV as a vector in clinical practice. Through quantitative PCR experiments, it was found that the HBoV1 auxiliary system composed of modified BocaSR significantly improved the level of AAV progeny virus production, which can be increased by more than 4 times, which can greatly reduce the cost of gene therapy using AAV as a vector, and has great development potential. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0018] Figure 1 These are the results of transfection of AAV, NP1NS2 and BocaSR in cells with knockdown of XPO5; A is the identification of nuclear-cytoplasmic separation 48 hours after transfection of AAV, NP1NS2 and BocaSR in cells with knockdown of XPO5, and B is the distribution of BocaSR in the nucleus and cytoplasm.

[0019] Figure 2 The results show that knocking down XPO5 in HEK293 cells can inhibit the replication of BocaSR in human bocavirus-assisted AAV; A is the construction of two stable cell lines with knockdown of XPO5 gene by lentiviral system, and the knockdown effect of XPO5 gene was detected by qPCR (statistical significance was determined by data processing, *** indicates P<0.001); B is Western Blot detection of the expression of endogenous XPO5 in control cells and knockdown stable cell lines; C is the transfection of AAV, NP1NS2, Vector, BocaSR, BocaSR in control cells and cells with knockdown of XPO5 gene 85TG / AC86The plasmid was used to extract RNA after 48 hours, and the expression of BocaSR was detected by Northern Blot; D was detected by Western Blot to detect the expression of AAV-related proteins; E was detected by Southern Blot to detect the replication of AAV genome in control cells and cells with XPO5 gene knockdown; F was detected by qPCR to detect the packaging level of AAV progeny viruses in the three groups of cells (statistically significant as determined by data processing, ** indicates P<0.01, *** indicates P<0.001); G was quantified statistics of the data in (F) (statistically significant as determined by data processing, ** indicates P<0.01, *** indicates P<0.001).

[0020] Figure 3 Overexpression of XPO5 in HEK293 cells can promote the replication of BocaSR-assisted AAV in human bocavirus; A is the Western Blot detection of the expression levels of AAV-related proteins in the FLAG-Vector, FLAG-XPO5, and FLAG-GFP groups; B is the Southern Blot detection of the AAV genome replication in Figure A; C is the qPCR detection of the AAV DNA progeny virus packaging level in the experiment in Figure A (statistically significant was determined through data processing, ** indicates P<0.01, ns indicates no significant difference).

[0021] Figure 4 The transformation of BocaSR and its localization distribution detection; A is the schematic diagram of the predicted secondary structure of BocaSR after transformation, and the red mark in the figure indicates the transformed base site; B is the transfection of Vector, BocaSR, and BocaSR in HEK293 cells G139T 、BocaSR A1C 、BocaSR 12-G / AT139 and BocaSR 1A- / CA12 Plasmid, 48h later, samples were collected and protein samples of the nucleus and cytoplasm were extracted by nuclear-cytoplasmic separation, and α-Tubulin and LaminA / C were detected by Western Blot; C is the RNA sample of the nucleus and cytoplasm extracted by nuclear-cytoplasmic separation experiment, and the distribution position of BocaSR in the nucleus and cytoplasm was detected by Northern Blot; in the figure, C represents cytoplasm, N represents nucleus, T represents total RNA, the red arrow in the figure indicates the position of BocaSR, and the * in the figure indicates the RNA degradation band caused during the experiment.

[0022] Figure 5The modified BocaSR can enhance AAV replication; A is Western Blot detection of the expression level of AAV-related proteins; B is Southern Blot detection of the replication of the AAV genome; C is qPCR detection of the packaging level of progeny viruses in each group of cells; D is the quantitative statistics of the qPCR results of the modified BocaSR and the wild-type BocaSR in Figure C (through data processing and analysis, *** indicates P<0.001).

[0023] Figure 6 The modified BocaSR exerts its effect by inhibiting the phosphorylation of PKR; A is the Western detection of the expression of recombinant Anti-PKR (phospho T451) antibody (T451) and Anti-EIF2S1 (phospho S51) antibody (S51) 48 hours after transfection; B is the Western Blot detection of the interaction between PKR and BocaSR and its mutants; C is the Northern Blot detection of the expression of BocaSR and VAI, the red arrows in the figure indicate the positions of BocaSR and VAI, Lowexposure: low exposure level, High exposure: high exposure level; D is the Western Blot detection of the interaction between PKR (1-184) and BocaSR and its mutants; E is the RNA immunoprecipitation detection of the interaction between PKR (1-184) and BocaSR and its mutants, the red arrows indicate the positions of BocaSR and VAI, respectively, and the * in the figure indicates the RNA degradation band caused during the experiment. DETAILED DESCRIPTION

[0024] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0025] Unless otherwise specified, the experimental methods used in the following experimental examples are all conventional methods; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.

[0026] Example 1 The present invention screens host cell factors to regulate the efficiency of BocaSR-assisted AAV replication in the HBoV1-assisted system and finds that the XPO5 gene can be regulated.

[0027] This application constructs a lentiviral knockdown system for the XPO5 gene: First, search for the mRNA of the XPO5 gene, and then design the shRNA sequence according to the Merck official website (pre-designed shRNA (sigmaaldrich.cn)): shXPO5-1: CCAGATGTTTCGAACACTAAA; shXPO5-2: CCGAGAAGTCATGGACCTAAT; Then design the shRNA oligos sequence according to the shRNA sequence, and the primers for amplifying the shRNA oligos sequence are as follows: shXPO5-1-F: CCGGCCAGATGTTTCGAACACTAAACTCGAGTTTAGTGTTCGAAACATCTGGTTTTTG; shXPO5-1-R: AATTCAAAAACCAGATGTTTCGAACACTAAACTCGAGTTTAGTGTTCGAAACATCTGG; shXPO5-2-F: CCGGCCGAGAAGTCATGGACCTAATCTCGAGATTAGGTCCATGACTTCTCGGTTTTTG; shXPO5-2-R: AATTCAAAAACCGAGAAGTCATGGACCTAATCTCGAGATTAGGTCCATGACTTCTCGG.

[0028] The steps for constructing lentivirus and knocking down the XPO5 gene cell line were performed according to the instructions of Addgene: Protocol - pLKO.1 –TRC CloningVector. The shRNA of the XPO5 gene was constructed in the pLKO.1 plasmid, packaged into lentivirus in HEK293T cells, and the lentivirus was transfected into HEK293 cells to construct the XPO5 gene knockdown cell line.

[0029] Preparation of auxiliary system: The construction of pIAAV plasmid was based on Human Bocavirus 1 NP1 which acts as an ssDNA-binding protein to help AAV2 DNA replication and cooperates with RPA to regulate AAV2 capsid expression. The NP1NS2 plasmid is pCAG-Myc-NP1NS2 plasmid. The nucleic acid sequence of NP1NS2 is cut with EcoRI and NotI and then inserted into the pCAGGS-Myc mammalian expression plasmid. The sequence of the obtained recombinant plasmid is shown in SEQ ID No.6.

[0030] The construction of BocaSR plasmid was based on Parvovirus Expresses a Small Noncoding RNA That Plays an Essential Role in Virus Replication.

[0031] The transfection steps are as follows (taking a 2 cm dish as an example): (1) Prepare the HEK293 cell line in advance and observe its growth density under a microscope. If the cell density is about 70%-80%, transfection can be performed.

[0032] (2) Prepare serum-free and antibiotic-free DMEM and transfection reagent. The mass of plasmid that can be transfected in a 2 cm culture dish is 2 μg, including 500 ng of pIAAV plasmid, 1000 ng of NP1NS2 plasmid, and 500 ng of BocaSR plasmid. The required ratio of transfection reagent (PEI) to transfection plasmid is 3:1, that is, 6 μL of transfection reagent is required.

[0033] (3) Prepare two 1.5 mL centrifuge tubes and add 100 μL of serum-free and antibiotic-free DMEM to each tube. Add the corresponding volume of plasmid to one tube and 6 μL of transfection reagent to the other tube. Mix the two tubes of liquid in one centrifuge tube and then keep it away from light for 25 min.

[0034] (4) After the time is up, evenly drop the liquid in the centrifuge tube into the culture dish, and then place it in a 37°C, 5% CO2 incubator.

[0035] (5) After 24 h of culture, replace the culture medium with fresh medium containing 2.5% serum and antibiotics. After 48 h, collect the cells to prepare samples for Western blot and Southern blot.

[0036] (6) After collecting the sample, wash the cells once with PBS, then add trypsin to digest for 1 minute, discard the trypsin, stop the digestion with 1 mL of culture medium and transfer the cells to a 1.5 mL EP tube. Centrifuge at 1000g for 3 minutes at 4°C, discard the supernatant, add nuclear-cytoplasmic separation lysis buffer RLN (add RI and 1 mM DTT before use), let stand on ice for 5 minutes and then centrifuge at low speed. At this time, the supernatant is the cytoplasm and the bottom precipitate is the nucleus. Wash the nucleus at least three times with RLN Buffer, add 2 × SDS Loading Buffer to the obtained sample, and detect the nuclear-cytoplasmic separation by WB. Tubulin indicates the cytoplasm and LaminA / C indicates the nucleus. The results are shown in the figure. Figure 1 As shown in A.

[0037] (7) Nuclear-cytoplasmic separation was performed as described in Human Bocavirus 1 NP1 acts as an ssDNA-binding protein to help AAV2 DNA replication and cooperates with RPA to regulate AAV2 capside expression. RNA was extracted from the samples collected for nuclear-cytoplasmic separation, and the distribution of BocaSR in the nucleus and cytoplasm was detected by Northern Blot. C represents cytoplasm, and N represents nucleus. Low exposure: low exposure level, High exposure: high exposure level. The * in the figure indicates RNA degradation bands caused during the experiment.

[0038] In this example, two HEK293 cell lines with knockdown of XPO5 were first constructed ( Figure 2 A, 2B), after knocking down the XPO5 gene, the NP1NS2 plasmid, BocaSR plasmid and pIAAV plasmid in the HBoV1 auxiliary system were transfected. After 48 hours, the nuclear-cytoplasmic separation technology and Northern Blot experiments showed that the distribution of BocaSR in the cell nucleus increased ( Figure 2 C), and through western blot experiments, it was found that the Boca virus auxiliary system composed of BocaSR assisted AAV replication to produce less AAV capsid protein VP expression ( Figure 2 D) Southern blot experiments revealed that the HBoV1 helper system composed of BocaSR significantly reduced the level of AAV genome replication ( Figure 2 E), and quantitative PCR experiments found that the level of AAV progeny virus produced by the BocaSR-comprising Boca virus auxiliary system decreased by 77.51% and 30.61% respectively ( Figure 2 F, 2G).

[0039] Example 2: Study on the function of overexpressed XPO5 gene Genomic DNA was extracted from A549 cells and used as a template to retrieve the XPO5 gene. The XPO5 gene was inserted into the PCDH-3xFLAG vector to obtain the recombinant plasmid FLAG-XPO5, and XPO5 was exogenously overexpressed in HEK293 cells.

[0040] The preparation of the auxiliary system is described in Example 1.

[0041] The NP1NS2 plasmid, BocaSR plasmid and pIAAV plasmid in the HBoV1 auxiliary system were transfected into the above-mentioned XPO5-overexpressing HEK293 cells. After 48 hours of culture, the nuclear-cytoplasmic separation technique and Northern Blot experiments showed that the distribution of BocaSR in the cytoplasm increased, and the western blot experiment showed that the HBoV1 auxiliary system composed of BocaSR assisted AAV replication to produce increased expression of AAV capsid protein VP ( Figure 3 A) Southern blot experiments revealed that the HBoV1 helper system composed of BocaSR significantly increased the level of AAV genome replication ( Figure 3 B), and quantitative PCR experiments found that the level of AAV progeny virus produced by the HBoV1 auxiliary system composed of BocaSR in the experimental group overexpressing XPO5 increased by 3.10 times ( Figure 3 C).

[0042] Example 3: Modification of the BocaSR sequence The sequence of BocaSR is a small coding RNA produced by HBoV1 itself, and its own sequence is SEQ ID No.1. We then designed four modified BocaSRs to increase the yield of progeny viruses produced by the HBoV1 auxiliary system. The four new modified BocaSRs are: BocaSR G139T (G mutated to T at position 139), BocaSR A1C (A mutated to C at position 1), BocaSR 12 -G / AT139 (A added at position 12, G mutated to T at position 139) and BocaSR 1A- / CA12 (A at position 1 mutated to C, A was added at position 12) The sequences are shown in SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4 or SEQ ID No. 5, and their secondary structures were predicted ( Figure 4 A).

[0043] These sequences were constructed into pGEM-3Z (p3Z) vectors respectively, as follows: BocaSR G139T The sequence of SEQ ID No. 2 was constructed on the p3Z vector (Promega.Madison, Wl) by homologous recombination with Primer 1-F, Primer 1-R, Primer 2-R, and Primer2-F as templates to obtain BocaSR G139T Recombinant plasmid p3Z-BocaSR G139T .

[0044] Primer 1-F:ggggggagcttttttgtt; Primer 1-R:atctacacgacggggagt; Primer 2-R:aacaaaaaagctccccccacaatgtacaagggctgtcg; Primer 2-F:actccccgtcgtgtagataactacgatacggggagggct.

[0045] BocaSR A1C The sequence of SEQ ID No. 3 was constructed on the P3Z vector to obtain BocaSR using the sequence of SEQ ID No. 3 as a template and Primer 5-F, Primer 1-R, Primer 2-F, and Primer 6-R as templates through homologous recombination. A1C Recombinant plasmid p3Z-BocaSR A1C .

[0046] Primer 5-F:ttctgcttacCagttcct; Primer 1-R:atctacacgacggggagt; Primer 2-F:actccccgtcgtgtagataactacgatacggggagggct; Primer 6-R: aggaactGgtaagcagaagcaaaaaagaggcttataag.

[0047] BocaSR G139T As a template, Primer 7-F, Primer 1-R, Primer2-F, Primer 7-R were used as templates, and the sequence shown in SEQ ID No. 4 was constructed on the P3Z vector to obtain BocaSR G139T Recombinant plasmid p3Z-BocaSR G139T .

[0048] Primer 7-F:caagttcctcctAcaatg; Primer 1-R:atctacacgacggggagt; Primer 2-F:actccccgtcgtgtagataactacgatacggggagggct; Primer 7-R:gTaggaggaacttgtaagcagaagcaaaaaagaggctt.

[0049] BocaSR 1A- / CA12 As a template, Primer 3-F, Primer 1-R, Primer 2-F, Primer 4-R were used as templates, and the sequence shown in SEQ ID No. 5 was constructed on the P3Z vector to obtain BocaSR 1A- / CA12 Recombinant plasmid p3Z-BocaSR 1A- / CA12 .

[0050] Primer 3-F:gcttacCagttcctcctAcaatg; Primer 1-R:atctacacgacggggagt; Primer 2-F:actccccgtcgtgtagataactacgatacggggagggct; Primer 4-R: cattgTaggaggaactGgtaagcagaagcaaaaaagag.

[0051] BocaSR G139T Recombinant plasmid, BocaSR A1C Recombinant plasmid, BocaSR G139T Recombinant plasmids and BocaSR 1A - / CA12 The recombinant plasmids were transfected into HEK293 cells, and samples were collected 48 hours later to extract protein samples from the nucleus and cytoplasm by nuclear-cytoplasmic separation. Western Blot was used to detect α-Tubulin and LaminA / C. These four recombinant plasmids were transcribed into non-coding RNA with a hairpin structure. Nuclear-cytoplasmic separation technology and Northern Blot experiments revealed that the wild-type BocaSR was mainly distributed in the nucleus, while the four new modified BocaSRs were significantly more distributed in the cytoplasm ( Figure 4 B, 4C).

[0052] Referring to the transfection steps in Example 1, the four modified BocaSR G139T 、BocaSR A1C 、BocaSR 12 -G / AT139 and BocaSR 1A- / CA12 NP1, NS2 and AAV plasmids in the HBoV1 helper system were transfected into HEK293 cells respectively.

[0053] Prepare a six-well plate of HEK293 cells, transfect the AAV plasmid and the modified BocaSR auxiliary system in the plate, and use the wild-type BocaSR auxiliary system as a control. After 48 hours, extract Hirt DNA to prepare Southern samples, and keep a certain amount of protein samples. Western Blot detects the expression level of AAV-related proteins. The experiment found that the BocaSR-composed Boca virus auxiliary system assisted AAV replication to produce an increase in the expression of AAV capsid protein VP ( Figure 5 A) Southern blot experiments revealed that the HBoV1 helper system composed of BocaSR significantly increased the level of AAV genome replication ( Figure 5 B), and according to the same transfection ratio as in A (AAV plasmid: NP1NS2 plasmid: BocaSR mutant plasmid is 1:2:1), samples were collected after 48 hours, AAV lysis Buffer was added to extract AAV genomic DNA, and qPCR was used to detect the packaging level of progeny viruses in each group of cells; quantitative PCR experiments found that the HBoV1 auxiliary system composed of BocaSR assisted AAV to produce progeny viruses at a level that was more than 4 times higher ( Figure 5 C, 5D).

[0054] 48 h after transfection, cells were directly lysed with 2×SDS Loading Buffer mixed with phosphatase inhibitors, and the expression of p-PKR and p-EIF2α was detected by Western blot. G139T 、BocaSR A1C 、BocaSR 12-G / AT139 and BocaSR 1A- / CA12 In HEK293 cells, PKR activity can be inhibited. Figure 6 A).

[0055] HEK293 cells were transfected with PKR plasmids with FLAG tags and modified BocaSR plasmids. Wild-type BocaSR and VAI were used as controls. Samples were collected 48 h after transfection, lysate was added, and a small amount of supernatant was mixed with 2×SDS Loading buffer as protein input sample. G139T 、BocaSR A1C 、BocaSR 12-G / AT139 and BocaSR 1A- / CA12 They can interact with PKR in HEK293 cells ( Figure 6 B).

[0056] The RNA of the input and IP samples was extracted by Trizol method, and the expression of BocaSR and VAI was detected by Northern Blot. The red arrows in the figure indicate the positions of BocaSR and VAI. The IP results showed that the modified BocaSR and VAI had obvious bands compared with the control. It was further found that BocaSR G139T 、BocaSR A1C 、BocaSR 12-G / AT139 and BocaSR 1A- / CA12 In HEK293 cells, it mainly binds to the double-stranded RNA binding region of PKR (amino acids 1-184) (Low exposure: low exposure level, High exposure: high exposure level) ( Figure 6 CE).

[0057] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A cell line for enhancing the function of the HBoV1 helper system, characterized in that: The cell line contains an XPO5 gene overexpression vector.

2. The cell line for enhancing the function of the HBoV1 helper system according to claim 1, characterized in that: The cell line is a mammalian cell line or a cancer cell line; the XPO5 gene overexpression vector is obtained by inserting the XPO5 gene into the PCDH-3xFLAG vector.

3. A HBoV1 auxiliary system, characterized in that: Includes plasmids expressing NP1 and NS2 and a plasmid expressing BocaSR.

4. The HBoV1 auxiliary system according to claim 3, characterized in that: The nucleotide sequence of the BocaSR is shown as SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4 or SEQ ID No.

5.

5. Use of the cell line described in claim 1 or 2 in improving the efficiency of AAV replication assisted by the HBoV1 helper system described in claim 3 or 4.

6. A method for increasing the replication level of AAV, characterized in that: The steps are: (1) Construct an overexpression vector of the XPO5 gene and transfer it into a cell line to overexpress the XPO5 protein; (2) By transfecting the transfected cell line in step (1) with plasmids expressing NP1 and NS2, a plasmid expressing BocaSR, and a plasmid expressing AAV2, the AAV replication level can be increased.

7. The method for increasing the AAV replication level according to claim 5, characterized in that: The cell line in step (1) is a mammalian cell line or a cancer cell line.

8. The method for increasing the AAV replication level according to claim 5, characterized in that: In the step (2), the plasmid for expressing NP1 and NS2 is obtained by inserting the NP1 and NS2 genes into pCDNA3.1-FLAG, PCDNA3.1-MyC or pEGFP-C2 plasmid, and the plasmid for expressing AAV2 is pIAAV2 plasmid.

9. The method for increasing the AAV replication level according to claim 5, characterized in that: The plasmid expressing BocaSR is obtained by inserting the sequence of mutant BocaSR into PGEM-3Z or pLKO.1 plasmid, wherein the sequence of mutant BocaSR is shown as SEQ ID No.2, SEQ ID No.3, SEQ ID No.4 or SEQ ID No.

5.

10. The method for increasing the AAV replication level according to claim 5, characterized in that: The addition ratio of the plasmid expressing NP1 and NS2, the plasmid expressing BocaSR, and the plasmid expressing AAV2 is 2:1:1.

Citation Information

Cited By

  • Improved HBoV1 auxiliary system and application thereof in efficient replication of AAV2

    CN120944977A